Provided by Tiger Trade Technology Pte. Ltd.

Rocket Pharmaceuticals, Inc.

3.53
+0.02000.57%
Post-market: 3.52-0.0100-0.28%19:30 EDT
Volume:913.30K
Turnover:3.19M
Market Cap:387.50M
PE:-20.76
High:3.55
Open:3.53
Low:3.38
Close:3.51
52wk High:5.45
52wk Low:2.53
Shares:109.77M
Float Shares:84.96M
Volume Ratio:0.75
T/O Rate:1.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1700
EPS(LYR):-2.0100
ROE:-4.77%
ROA:-28.42%
PB:1.05
PE(LYR):-1.76

Loading ...

PRV reception could net Rocket $100M-$200M, says LifeSci Capital

TIPRANKS
·
Mar 28

Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush

TIPRANKS
·
Mar 28

BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services

Reuters
·
Mar 27

Rocket Pharmaceuticals Shares Reverse Premarket Gains, Last Down 10%

THOMSON REUTERS
·
Mar 27

Rocket Pharma Exec Says Co in Active Discussions and Engaging With External Parties Regarding the Sale of the Priority Review Voucher

THOMSON REUTERS
·
Mar 27

Rocket Pharma Exec Says Co Has Been Engaging With Payers to Ensure Reimbursement Ahead of Launch - Conf Call

THOMSON REUTERS
·
Mar 27

Rocket Pharma Exec Says Co Anticipates Commercial Availability of Kresladi in Q4 of 2026 - Exec Says

THOMSON REUTERS
·
Mar 27

Rocket Pharmaceuticals Shares up 10.2% Premarket After US FDA Approve Co's Therapy for Deadly Childhood Disorder

THOMSON REUTERS
·
Mar 27

Top Premarket Gainers

MT Newswires Live
·
Mar 27

Rocket Pharmaceuticals gains FDA accelerated approval for KRESLADI in severe pediatric LAD-I; FDA grants rare pediatric disease priority review voucher

Reuters
·
Mar 27

Rocket Pharmaceuticals Announces FDA Approval of Kresladi™ for Pediatric Patients With Severe Leukocyte Adhesion Deficiency-I (Lad-I)

THOMSON REUTERS
·
Mar 27

Rocket Pharmaceuticals announces 2026 annual stockholders meeting

Reuters
·
Mar 25

Rocket Pharma Advances BAG3 Heart Disease Study, Bolstering Long-Term Gene Therapy Story

TIPRANKS
·
Mar 21

Rocket Pharmaceuticals Inc - Enters Sales Agreement With Cantor Fitzgerald & Co. for Atm Offering up to $100 Mln - SEC Filing

THOMSON REUTERS
·
Mar 11

Rocket Pharmaceuticals signs equity distribution deal for USD 100 million at-the-market offering

Reuters
·
Mar 11

Rocket Pharmaceuticals Inc Files for Mixed Shelf of up to $400 Mln - SEC Filing

THOMSON REUTERS
·
Mar 03

Rocket Pharmaceuticals price target raised to $3 from $2 at Goldman Sachs

TIPRANKS
·
Mar 02

Chardan Capital Sticks to Its Buy Rating for Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Feb 28

Rocket Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Feb 27

Cantor Fitzgerald Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Feb 27